REMARKS

Claims 24 and 26 have been cancelled without prejudice. Claim 25 has been amended so as to convert it from a dependent claim to an independent claim. Claims 27 and 28 are newly added and are directed to processes for inhibiting hexoaminidase and glycosidase respectively with the compound of Claim 25. Support for Claims 27 and 28 is found in the specification at page 25, line 1 - page 26, end and in Figures 3 and 4. Claims 25 and 27-28 are the only pending claims under examination.

Rejection under 35 U.S.C. 102(b):

Claim 24 was rejected under 35 U.S.C. 102(b), as being anticipated by Barta et al., i.e., US Pat. No. 5,663,342. The cancellation of claim 24 obviates this basis of rejection.

Rejection under 35 U.S.C. 103(a):

Claims 24-26 have been rejected under 35 U.S.C. 103(a), as being patentably obvious over Barta et al., i.e., US Pat. No. 5,663,342. Claims 24 and 26 have been cancelled. Applicant traverses this basis of rejection with respect to claim 25.

Examiner states that Barta discloses a compound where W of Formula III is NH bonded to an acyl group. Examiner is mistaken. Barta does not define W of Formula III in this manner. Examiner says that Barta defines W of Formula to include (R9R10)(CO)O and R10R11N. Neither R10 nor R11 is allowed to be an acyl group. Accordingly, neither of these groups forms an NAc group. Compound 51, which

includes an NAc group, falls outside of the compounds of Formula III. The exclusion of Compound 51 from Formula III of Barta would indicate that Compound 51 was not considered by Barta to be a preferred compound.

Barta discloses that the a-glucosidase and b-glucosidase activity for compound 51 is poor. Furthermore, all of the compounds listed explicitly and tested in this patent have *N*-alkyl or *N*-aralkyl groups that are larger than *n*-butyl and some are branched and substantially more bulky. The relatively low activity of compound 51 with respect to the glucosidases versus other compounds would not motivate one to make analogs of compound 51. Indeed, Barta discloses no analogs of 51 that had smaller R groups on the nitrogen. Accordingly, Barta teaches away from small R groups on the nitrogen.

In contrast, Figures 3 and 4 of the present application disclose that Compound **4**, i.e., the compound of Claim 25, has significantly enhanced inhibitory activity over prior art compounds having larger R groups on the nitrogen.

Accordingly, the compound of Claim 25 is patentably unobvious over Barta. Withdrawal of this basis of rejection is requested.

Rejection under 35 U.S.C. 112, second paragraph:

Claims 24-26 have been rejected under 35 U.S.C. 112, second paragraph, for lack of clarity. Claims 24 and 26 have been cancelled. Claim 25 has been amended so as to enhance its clarity and is directed to the indicated compound. Claims 27 and 28 have been added and are directed to the corresponding processes for inhibiting hexoaminidase and glycosidase respectively. Applicant's amendments overcome this basis of rejection.

Summary:

Claims 24 and 26 have been cancelled. Claim 25 has been amended. Claims 27-28 have been added. Claims 25 and 27-28 are pending and are patentably unobvious under 35 U.S.C. 103(a) and patentably definite under 35 U.S.C. 112, second paragraph. Allowance of claims 25 and 27-28 is respectfully requested.

Respectfully submitted,



Donald G. Lewis
Reg. No. 28,636
The Scripps Research Institute
10550 N. Torrey Pines Road TPC-8
San Diego, CA 92037
April 18, 2006
(858) 784-2937